Evaluating Somatostatin Receptor Expression in Metastatic Breast Cancer Patients
Official title: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
Run by University Hospital, Grenoble · NCT06611891 · Data updated 2026-11-12
This study is testing if a special type of PET scan can help women with metastatic breast cancer see how their cancer is spreading and what treatment options might work best for them.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | Women only |
| Enrollment | 25 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Status | Recruiting |
| Started | January 6, 2025 |
| Main results expected | October 2025 |
| Study ends | October 2026 |
| Registry record updated | March 4, 2025 |
| Trial ID | NCT06611891 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women over 18 with metastatic breast cancer who have completed at least one line of systemic therapy and have identifiable metastatic lesions.
✕Probably not a fit
Patients with other active neoplastic diseases or those who are minors will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study aims to evaluate somatostatin receptor expression using PET scans with 68Ga-DOTATOC in women diagnosed with metastatic breast cancer. It is a prospective, monocentric, non-controlled, and open-label study that includes patients who have undergone at least one line of systemic therapy. The study focuses on assessing the feasibility of using 68Ga-DOTATOC PET scans to identify and evaluate metastatic lesions in patients with specific receptor profiles. The goal is to improve understanding of metastatic breast cancer progression and treatment options.
Why it matters
Potential benefit: If successful, this study could enhance the ability to identify and target metastatic breast cancer lesions, potentially leading to improved treatment outcomes.
How similar studies have gone: While the use of 68Ga-DOTATOC PET scans has been validated in neuroendocrine tumors, its application in metastatic breast cancer is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 * Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer * Patient labeled on the primary lesion ER+HER2- (20) * Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan * Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan * No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan. * Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan * Person affiliated to or benefiting from social security * Person who has given written informed consent Exclusion Criteria: * Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor) * Known allergy to 68Ga-DOTATOC or its excipients * Subject refusing to sign the consent to participate * Minor subject * Subject excluded from another study * Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP) * Subject cannot be contacted in case of emergency
Where it's running
-
CHU Grenoble Alpes
Grenoble, France Recruiting
Study contacts
- Principal investigator: Loic DJAILEB — CHU Grenoble Alpes
- Study coordinator: Marine FAURE
- Email: MFaure6@chu-grenoble.fr
- Phone: 0476766872
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Decision Support Tool for People with Advanced Breast Cancer
This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.
-
HER2-PET to Predict T-DXd Benefit in Advanced Breast Cancer
This study tests whether HER2-PET imaging can help predict how well T-DXd will work for adults with advanced HER2-positive or HER2-low breast cancer receiving the drug.
-
Nutrition awareness for women after non-metastatic breast cancer
This online program tests whether an educational brochure and short surveys can help women who have finished treatment for non-metastatic breast cancer recognize unhealthy processed foods and be willing to change their diet.
-
Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors
This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.
-
First-line Sacituzumab Govitecan for Advanced Untreated Triple-Negative Breast Cancer
This study tests whether Sacituzumab Govitecan can slow disease progression when given as a first treatment to adults with advanced triple-negative breast cancer who have not yet received treatment in the advanced setting.
-
OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1
This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.